Eltrombopag (Revolade®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001442
English
Authors' recommendations:
Eltrombopag (Revolade®) is recommended for use within NHS Wales in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon based therapy. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/607
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Hepatitis C, Chronic
- Benzoates
- Hydrazines
- Pyrazoles
- Thrombocytopenia
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.